RecruitingNCT04621279

Cool Prime Comparative Effectiveness Study for Mild HIE

COOLPRIME: Comparative Effectiveness for Cooling Prospectively Infants With Mild Encephalopathy


Sponsor

University of Texas Southwestern Medical Center

Enrollment

460 participants

Start Date

Jul 19, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

To determine effectiveness of therapy to improve neurodevelopmental outcomes in infants with mild HIE. To determine the adverse effects of Therapeutic Hypothermia (TH) in mild HIE on the neonate and his/her family. Determine heterogeneity of the treatment effect across key subgroups obtained in the first 6 hours after birth prior to the decision to initiate therapy.


Eligibility

Min Age: 36 Weeks

Inclusion Criteria13

  • Neonates born at ≥ 36 0/7 weeks
  • Mild Encephalopathy on neonatal neurologic exam within 6 hours after birth: defined as presence of at least 2 signs of mild, moderate, or severe encephalopathy with no more than 2 signs in the moderate or severe category.
  • Perinatal Acidosis based on at least one of the following (A or B):
  • pH ≤ 7.00 in any cord or first infant gas (arterial, venous, or capillary) within ≤ 60 min OR base deficit ≥ 16 in any cord or first infant gas (arterial, venous or capillary) within ≤ 60 min
  • If pH is between 7.01 and 7.15, OR base deficit is between 10 and 15.9 mmol/liter, OR blood gas is not available, an acute perinatal event is an additional criteria required (see below definition)
  • An acute perinatal event is defined by at least one of the following:
  • Apgar score at 10 min ≤ 5
  • Continued need for resuscitation at 10 min (chest compressions, bag mask ventilation, or positive pressure ventilation)
  • Uterine rupture, placental abruption, cord accident (prolapse, rupture, knot or tight nuchal cord)
  • maternal trauma, maternal hemorrhage, or cardiorespiratory arrest
  • fetal exsanguination from either vasa previa or feto-maternal hemorrhage, shoulder dystocia
  • Any evidence suggestive of acute perinatal event.
  • Infants are still eligible for enrollment in the COOLPRIME study if the cord or infant's first blood gas (arterial, venous, or capillary) is obtained \>60 minutes of life.

Exclusion Criteria7

  • Gestational age at birth \< 36 0/7 weeks
  • Birth weight \< 1800gm
  • Head circumference \<30cm
  • Congenital or chromosomal anomaly associated with abnormal neurodevelopment or death
  • Moderate or Severe HIE of 3 or more moderate or severe abnormalities on COOLPRIME Sarnat exam within 6 hours of life
  • Any seizures within first six hours of life
  • Redirection of care is being considered

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURENormothermia

Usual care for first 72 hours for neonates with mild encephalopathy maintaining core temperature (36.5°C ± 1 C).

PROCEDUREWhole body therapeutic hypothermia

Whole-body therapeutic hypothermia (33.5°C ± 0.5°C) for 72 hours began by 6 hours of age for neonates with mild encephalopathy per site standard of care practice.


Locations(1)

University of Texas Southwestern Medical Center

Dallas, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04621279